Official Title
Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination
Brief Summary

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic has been intensified by no population-based immunity to the severe acute respiratory disease coronavirus 2 (SARS-CoV2) and initially lack of effective treatments or vaccines available to mitigate the pandemic. Currently, two COVID-19 vaccines are available for vaccination in Europe through conditional marketing authorisation granted by the European Medicines Agency and further vaccine will be licensed. These vaccines have shown good vaccine efficacy in phase 3 vaccine trials. We will recruit subjects who will be prioritised for vaccination with the primary aim of comparing the immune responses after COVID-19 vaccination and natural SARS-CoV-2 infection. In Western Norway we have recruited cohorts of health care workers and patients infected with SARS-CoV-2 and will extend to COVID-19 vaccinees. Demographic, clinical data and repeated blood samples will be collected to evaluate the complications and kinetics, duration and breadth of the immune responses comparing natural infection to vaccination.

Detailed Description

The primary aim of this study is

- To compare immune responses after natural SARS-CoV-2 infection and COVID-19 vaccination
The secondary aims are

- To compare the duration and breadth of antibody responses between natural infection and
vaccination.

- To investigate the duration and breadth of B and T cellular responses between natural
infection and vaccination.

- To evaluate the short and long term complications after natural infection and
vaccination.

- To find out if previous infection skews the immune response after vaccination.

- To study reinfection after natural infection and vaccination.

Recruiting
COVID19

Biological: covid-19 vaccine

vaccination

Eligibility Criteria

Inclusion Criteria:

- subjects prioritized by national vaccination program

Exclusion Criteria:

- Children

- unable or unwilling to provide informed consent

Eligibility Gender
All
Eligibility Age
Minimum: 20 Years ~ Maximum: 100 Years
Countries
Norway
Locations

University of Bergen
Bergen, Norway

Investigator: Rebecca J Cox, PhD
Contact: 45242974
rebecca.cox@uib.no

Contacts

Rebecca J Cox, PhD
+4745242974
rebecca.cox@uib.no

Nina Langeland, MD
+4741616450
nina.langeland@uib.no

Rebecca J Cox, PhD, Principal Investigator
University of Bergen

Haukeland University Hospital
NCT Number
Keywords
COVID19
Vaccine
SARS-CoV-2 antibody
MeSH Terms
COVID-19